Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
549.3 USD | -2.05% | -0.57% | +18.64% |
May. 28 | Mckesson Insider Sold Shares Worth $392,895, According to a Recent SEC Filing | MT |
May. 28 | Mckesson Insider Sold Shares Worth $7,116,764, According to a Recent SEC Filing | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The stock, which is currently worth 2025 to 0.2 times its sales, is clearly overvalued in comparison with peers.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.64% | 72.89B | C+ | ||
-6.00% | 23.48B | C+ | ||
+4.65% | 8.67B | C | ||
+9.32% | 8.51B | B | ||
-25.47% | 7.71B | B- | ||
+13.37% | 5.21B | B- | ||
+1.58% | 4.23B | B- | ||
+5.71% | 4.08B | B+ | ||
+1.24% | 3.99B | B | ||
+20.58% | 3.67B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MCK Stock
- Ratings McKesson Corporation